naphthalimides has been researched along with Glioblastoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, KL; Jia, Y; Li, P; Qiao, Y; Zhang, MM | 1 |
| Conti, L; Dallanoce, C; De Amici, M; Del Bufalo, D; Guerriero, C; Matera, C; Tata, AM | 1 |
2 other study(ies) available for naphthalimides and Glioblastoma
| Article | Year |
|---|---|
New Protocol-Guided Exploitation of a Lysosomal Sulfatase Inhibitor to Suppress Cell Growth in Glioblastoma Multiforme.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Fluorescent Dyes; Glioblastoma; Glucosides; Humans; Lysosomes; Naphthalimides; Prognosis; Sulbactam; Sulfatases | 2021 |
The Combined Treatment with Chemotherapeutic Agents and the Dualsteric Muscarinic Agonist Iper-8-Naphthalimide Affects Drug Resistance in Glioblastoma Stem Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Muscarinic Agonists; Naphthalimides; Neoplastic Stem Cells; Receptor, Muscarinic M2; Signal Transduction; Temozolomide | 2021 |